Stockscreener 앱 받기
1.94
6.28%
-0.13
시장 영업 전:
1.95
0.01
+0.52%
전일 마감가:
$2.07
열려 있는:
$2.0516
하루 거래량:
53,679
Relative Volume:
1.46
시가총액:
$13.57M
수익:
-
순이익/손실:
$-33.65M
주가수익비율:
-0.436
EPS:
-4.45
순현금흐름:
$-20.83M
1주 성능:
-15.65%
1개월 성능:
-10.80%
6개월 성능:
-32.64%
1년 성능:
-81.22%
1일 변동 폭
$1.90
$2.07
1주일 범위
$1.90
$2.5499
52주 변동 폭
$1.90
$10.33
미네르바 뉴로사이언스 Stock (NERV) Company Profile
명칭
Minerva Neurosciences Inc
전화
617-600-7373
주소
1601 TRAPELO ROAD, WALTHAM, MA
NERV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NERV
Minerva Neurosciences Inc
|
1.94 | 13.57M | 0 | -33.65M | -20.83M | -4.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.22 | 117.23B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
665.46 | 72.75B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
636.02 | 38.65B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.99 | 34.69B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
114.50 | 27.45B | 3.30B | -501.07M | 1.03B | -2.1146 |
미네르바 뉴로사이언스 Stock (NERV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-06-08 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-14 | 개시 | BTIG Research | Buy |
| 2019-10-02 | 재확인 | Chardan Capital Markets | Buy |
| 2019-09-25 | 개시 | Chardan Capital Markets | Buy |
| 2019-09-18 | 개시 | William Blair | Outperform |
| 2019-05-31 | 개시 | H.C. Wainwright | Buy |
| 2017-09-01 | 개시 | Citigroup | Buy |
| 2017-03-06 | 재개 | Jefferies | Buy |
| 2016-05-12 | 재개 | Jefferies | Buy |
모두보기
미네르바 뉴로사이언스 주식(NERV)의 최신 뉴스
Minerva Neurosciences stock hits 52-week low at $2.02 By Investing.com - Investing.com South Africa
Minerva Neurosciences (NASDAQ:NERV) Now Covered by Analysts at StockNews.com - Armenian Reporter
GHP Investment Advisors Inc. Reduces Stock Holdings in Silgan Holdings Inc. (NYSE:SLGN) - Armenian Reporter
Viasat (NASDAQ:VSAT) Announces Earnings Results, Misses Estimates By $0.70 EPS - Armenian Reporter
Promising Penny Stocks To Follow Today – February 04th - Armenian Reporter
Chronic Insomnia Market Outlook: Strong Growth Projected by 2032, Highlights DelveInsight - NEWSnet
Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated by Analysts at StockNews.com - Defense World
Investor Network: Minerva Neurosciences Inc to Host Earnings Call - ACCESS Newswire
Minerva Neurosciences Stock Hits 52-Week Low at $2.03 - MSN
StockNews.com Begins Coverage on Minerva Neurosciences (NASDAQ:NERV) - Defense World
Minerva Neurosciences (NASDAQ:NERV) vs. SciSparc (NASDAQ:SPRC) Financial Contrast - Defense World
Minerva Neurosciences Faces Listing Compliance Challenges as Nasdaq Grants Continued Listing Subject to ConditionsMinerva Neurosciences Inc. recently encountered challenges regarding its listing on The Nasdaq Capital Market as disclosed in a Form 8 - Defense World
Minerva Neurosciences secures Nasdaq listing extension By Investing.com - Investing.com South Africa
Minerva Neurosciences secures Nasdaq listing extension - Investing.com
StockNews.com Initiates Coverage on Minerva Neurosciences (NASDAQ:NERV) - Defense World
Minerva Neurosciences (NASDAQ:NERV) Now Covered by StockNews.com - Defense World
Future Industry Growth Of Cognitive Behavioral Therapy - openPR
Neurological stocks rise and fall on clinical data; index down - BioWorld Online
Minerva Neurosciences reports voting results from annual meeting By Investing.com - Investing.com Nigeria
Minerva Neurosciences stock hits 52-week low at $2.07 - Investing.com India
Minerva Neurosciences stock hits 52-week low at $2.07 By Investing.com - Investing.com UK
Minerva Neurosciences reports voting results from annual meeting - Investing.com
Minerva Neurosciences (NASDAQ:NERV) Earns Sell Rating from Analysts at StockNews.com - Defense World
Minerva Neurosciences : ROSEN, RECOGNIZED INVESTOR COUNSEL, Reminds Minerva Neurosciences, Inc. Investors of Important Deadline in Securities Class ActionNERV - Marketscreener.com
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.25% - MSN
Reviewing Vistagen Therapeutics (NASDAQ:VTGN) and Minerva Neurosciences (NASDAQ:NERV) - Defense World
500: Something went wrong - Investing.com
Minerva Neurosciences stock hits 52-week low at $2.25 By Investing.com - Investing.com Canada
Minerva Neurosciences’ (NERV) “Neutral” Rating Reiterated at HC Wainwright - Defense World
Minerva Neurosciences Reports Positive Earnings Amid FDA Challenges - TipRanks
Minerva Neurosciences: Q3 Earnings Snapshot - San Francisco Chronicle
Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates - GlobeNewswire
Minerva Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Major Depressive Disorder Market Expected to Experience Major Growth by 2034, According to DelveInsight | Takeda, Otsuka Pharma, AbbVie, SAGE Therapeutics, Forest Laboratories, Axsome Therapeutics - The Globe and Mail
Cognitive Impairment Disorders Treatment A Game Changer for Global Finance Forecast-Eli Lilly and Company, AstraZeneca, – IndiaPolitics.com - IndiaPolitics.com
Japan Receptor Tyrosine Protein Kinase ERBB 4 Industry Size, Share, Price, Trends, Forecast (2024-2034) - IndiaPolitics.com
Minerva Neurosciences (NASDAQ:NERV) Share Price Passes Below 200-Day Moving Average – What’s Next? - Defense World
Schizophrenia Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Reviva Pharma, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharma, Boehringer Ingelheim, Sunovion - Barchart
Neurological diseases index falls; Sarepta and Intra-Cellular report gains - BioWorld Online
Inari Medical director sells $1.83M in common stock - TipRanks
Intuitive Machines Shares Soar on NASA Pact for Near-Space Grid - Bloomberg
Intuitive Machines Stock Soars on New NASA Contract. This Is Big. - Barron's
Intuitive Machines Stock Is Soaring Wednesday: What's Going On? - Benzinga
Why Intuitive Machines Shares Are Trading Higher By Around 41%; Here Are 20 Stocks Moving Premarket - Benzinga
After-hours movers: Intuitive Machines, Casella Waste Systems, Galmed Pharma, Edgewise Therapeutics - Investing.com Australia
Minerva Neurosciences (NASDAQ:NERV) Receives New Coverage from Analysts at StockNews.com - Defense World
Rathbones Group PLC Increases Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) - MarketBeat
INmune Bio stock dips on $13M securities offering - MSN
미네르바 뉴로사이언스 (NERV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.27%
5.10%
자본화:
|
볼륨(24시간):